Monday, November 24, 2014

ILJIN withdraws damage claims against Isotechnika

ILJIN withdraws damage claims against Isotechnika

January 15, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” […]

Isotechnika’s NICAMs effective against Hepatitis C virus

Isotechnika’s NICAMs effective against Hepatitis C virus

December 6, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the NIH’s National Institute of Allergy and Infectious Diseases. Several NICAM compounds were tested for cross genotype activity using quantitative polymerase chain reaction in HCV replicons, […]

Isotechnika receives partial award in ICC arbitration

Isotechnika receives partial award in ICC arbitration

November 30, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received a partial award from the International Chamber of Commerce Court of Arbitration regarding its right to terminate a development, distribution and license (DDL) agreement with ILJIN Life Sciences of South Korea. The partial award provides that the DDL has not been terminated and the company’s contractual relationship with ILJIN […]

FDA clears Isotechnika for Phase 3 voclosporin trial

FDA clears Isotechnika for Phase 3 voclosporin trial

November 26, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received permission from the FDA to commence the first of two planned Phase 3 kidney transplant trials for its lead product candidate, voclosporin, under a special protocol assessment (SPA) from the FDA. The SPA was received after the FDA reviewed Isotechnika’s Phase 2b data and evaluated the proposed Phase 3 […]

Isotechnika gets added Canadian funding for NICAMs

Isotechnika gets added Canadian funding for NICAMs

July 17, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received approval for additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program. NRC-IRAP previously assisted Isotechnika in the discovery of a series of NICAMs that were shown to be potent inhibitors of a class of proteins called cyclophilins. Research […]

Isotechnika partner completes enrolment in Phase 3 uveitis study

Isotechnika partner completes enrolment in Phase 3 uveitis study

July 9, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) partner, Lux Biosciences, has completed patient enrolment in its Phase 3 clinical study using voclosporin (branded as Luveniq) for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. Lux anticipates that data from the Phase 3 study will be available early in the first quarter of […]

NIH agency to evaluate Isotechnika’s NICAMs

NIH agency to evaluate Isotechnika’s NICAMs

April 11, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has signed a three-year Non-Clinical Evaluation Agreement with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Under the accord, NIAID-funded contractors will evaluate the company’s portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs) as anti-viral agents. Isotechnika’s NICAM portfolio will be tested through NIAID’s preclinical services program for use […]

Isotechnika to present at BioPartnering NA 2012

Isotechnika to present at BioPartnering NA 2012

February 28, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster will participate in a BioPartnering North America 2012 conference workshop entitled, “Need + Innovation = Opportunity,” this afternoon at the Vancouver Convention Center. “We are delighted to be given this opportunity to share with a global audience the continued progress of our voclosporin program,” Dr. Foster said […]

Isotechnika ends existing license accord with ILJIN

Isotechnika ends existing license accord with ILJIN

January 31, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has exercised its right to terminate an existing development, distribution and license agreement with ILJIN Life Science of South Korea and is pursuing discussions to potentially change the current relationship with ILJIN in order to better advance its voclosporin program. As a result, Isotechnika has secured full rights to voclosporin for […]

ILJIN considering control position in Isotechnika

ILJIN considering control position in Isotechnika

January 6, 2012 by · Leave a Comment 

Tweet ILJIN Life Science of South Korea, the second largest shareholder of Isotechnika Pharma (TSX:ISA), has verbally informed Isotechnika’s board that ILJIN is planning to “increase their level of control within the company.” The verbal proposal was made by Daniel Park, Executive VP of ILJIN, who has resigned his position as Chief Business Officer of […]

Next Page »

Email Newsletters with Constant Contact
Google+